Abbott Laboratories (ABT) Income from Continuing Operations (2009 - 2026)

Abbott Laboratories has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 1077000000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 1077000000.0, down 18.72% year-over-year; the trailing twelve-month figure through Mar 2026 was 6276000000.0 (down 53.52% YoY), and the FY2025 annual result was 6524000000.0, down 51.32% from the prior year.
• Income from Continuing Operations came in at 1077000000.0 for Q1 2026 at Abbott Laboratories, down from 1776000000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 9229000000.0 in Q4 2024 to a low of 1033000000.0 in Q4 2022.
• The 5-year median for Income from Continuing Operations is 1436000000.0 (2023), against an average of 1979941176.47.
• Across the five-year window, Income from Continuing Operations jumped 478.98% in 2024 and sank 80.76% in 2025, its largest moves.
• Abbott Laboratories' Income from Continuing Operations stood at 1033000000.0 in 2022, then jumped by 54.31% to 1594000000.0 in 2023, then surged by 478.98% to 9229000000.0 in 2024, then tumbled by 80.76% to 1776000000.0 in 2025, then slumped by 39.36% to 1077000000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 1077000000.0 (Q1 2026), 1776000000.0 (Q4 2025), and 1644000000.0 (Q3 2025), per Business Quant data.